Impact of chemoradiotherapy on vaginal and sexual function of patients with FIGO IIb cervical cancer

The opinion regarding sexual and vaginal function of patients with advanced cervical cancer treated primarily by chemoradiotherapy has still not been formed, mainly due to inappropriate methodology as the control group was comprised of healthy women. The aim of this study is to, by means of intervie...

Full description

Saved in:
Bibliographic Details
Published in:Biomolecules & biomedicine 2011-02, Vol.11 (1), p.62-64
Main Authors: Ljuca, Dženita, Marošević, Goran
Format: Article
Language:English
Subjects:
Adult
Aged
Brachytherapy
cervical cancer
chemoradiotherapy
Coitus - physiology
Coitus - psychology
Combined Modality Therapy
Dose-Response Relationship, Drug
Dose-Response Relationship, Radiation
Drug Therapy
Female
Health Surveys
Humans
Middle Aged
Neoplasm Staging
Original
Prospective Studies
Radiotherapy
Retrospective Studies
Sexual Behavior - drug effects
Sexual Behavior - physiology
Sexual Behavior - radiation effects
sexual function
Treatment Outcome
Uterine Cervical Neoplasms - pathology
Uterine Cervical Neoplasms - physiopathology
Uterine Cervical Neoplasms - therapy
Vagina - drug effects
Vagina - physiology
Vagina - radiation effects
vaginal function
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The opinion regarding sexual and vaginal function of patients with advanced cervical cancer treated primarily by chemoradiotherapy has still not been formed, mainly due to inappropriate methodology as the control group was comprised of healthy women. The aim of this study is to, by means of interview, evaluate vaginal and sexual function of patients with advanced cervical cancer before and after chemoradiotherapy and compare the results. A number of 35 patients were irradiated by teleradiotherapy dose of 45 Gy in 25 fractions over 5 weeks to the pelvis and additional 20-24 Gy in 4-6 fractions were given by intracavitary HDR brachytherapy. Patients received 40 mg/m(2) of cisplatin once a week, which is a total of 4-6 cycles of cisplatin. Patients answered the questions in a form of a questionnaire specifically created for cervical cancer (EORTC-QLQ-Cx 24), for the period immediately before diagnosed cervical cancer (thus being a control group). They also answered the same questions for the period starting 12 months after the completion of concomitant chemoradiotherapy, and were an experimental group at the time. For the testing of statistical significance of differences among the examined groups parameter and non-parameter tests were used (the Wilcoxon signed ranks test and Student's t-test). The difference p
ISSN:1512-8601
2831-0896
1840-4812
2831-090X
DOI:10.17305/bjbms.2011.2628